Croda invests in Vaccine Adjuvants10 Jul 2019
Croda has strengthened its pharmaceutical offering by acquiring Brenntag Biosector (Biosector), for a total consideration of €72 million in cash.
The acquisition of Biosector will give Croda access to an industry renowned product portfolio of adjuvants, including the well-known brands Alhydrogel® and Adju-Phos®, as well as their technically advanced saponin-based adjuvant systems.
Through this acquisition, Croda will not only gain ownership to Biosector’s rich development pipeline for second and third generation adjuvant platforms but will also become the only adjuvant supplier in the world with an aseptic and GMP certified manufacturing site for vaccine adjuvants.
Croda will leverage its own dedicated global sales network to accelerate Biosector’s growth. Furthermore, the acquisition will enable Croda to better support their existing customers through increased breadth of offering and additional technical expertise in vaccine adjuvants.
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation